Disclosed are MC-3/MC-4 receptor ligands, the ligands having the following formula:
1
wherein A is a conformationally restricted ring system selected from the group consisting of:
a) non-aromatic carbocyclic rings;
b) aromatic carbocyclic rings;
c) non-aromatic heterocyclic rings;
d) aromatic heterocyclic rings;
wherein said rings comprises from 5 to 8 atoms; and W is a unit which preferable comprises D-1-fluorophenyalanine, Y comprises a heteroatom, and Z comprises an aromatic carbocyclic ring. Also disclosed are pharmaceutical compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 receptors.
本发明涉及MC-3/MC-4受体
配体,该
配体具有以下公式:1其中A是从以下群组中选择的构象限制环系统:a)非芳香烷环;b)芳香烷环;c)非芳香杂环;d)芳香杂环;其中所述环包含5到8个原子;W是一个单元,它最好包括D-1-
氟苯丙
氨酸,Y包括一个杂原子,Z包括一个芳香烷环。本发明还涉及包含所述
配体的制药组合物,以及通过MC-3/MC-4受体介导的治疗疾病的方法。